Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

NHL: early-phase trial registry

4 of 9 indexed NHL trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count

NHL: 9 US clinical trials tracked, 4 recruiting.

NHL is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

Enrollment posture brief

Registry condition nhl

OPEN 4 | RECR 44% | LATE 0 | EARLY 8 | RANK #1916 | SPON 3

Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%NHL (this)44%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near NHL

NHL lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for NHL on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. NHL is recruiting below its size-band peers.

    4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates NHL research.

    National Cancer Institute (NCI) accounts for 3 of 9 trials (33.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical NHL enrolment sits around 90 participants.

    Median target enrolment is 90 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. NHL research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 24

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2 132 participants

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Cancer Institute (NCI)

NCT04002947

RECRUITING Phase 1 128 participants

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Indapta Therapeutics

NCT06119685

RECRUITING NA 100 participants

SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors

Barbara Nemesure

NCT07161713

RECRUITING Phase 2 64 participants

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

University of Rochester

NCT03739502

ACTIVE NOT RECRUITING Phase 1 90 participants

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Cullinan Therapeutics

NCT05879744

ACTIVE NOT RECRUITING Phase 1 36 participants

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Synthekine

NCT05665062

ACTIVE NOT RECRUITING Phase 2 33 participants

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

National Cancer Institute (NCI)

NCT03789240

COMPLETED Phase 1 134 participants

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

National Cancer Institute (NCI)

NCT02315612

COMPLETED Phase 2 16 participants

Allogeneic Transplantation From Related Haploidentical Donors

Stanford University

NCT00185692

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4

Named interventions

Most-linked intervention names on NHL records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Rituximab Biological
2 trials
Cyclophosphamide Drug
2 trials
Anti-Thymocyte Globulin Drug
1 trials
non-myeloablative hematopoietic cell transplantation Procedure
1 trials
CD22-CAR Biological
1 trials
STK-009 Drug
1 trials
SYNCAR-001 Drug
1 trials
18F-FDG-PET/CT Scan15 Diagnostic test
1 trials

US sites by state

Facility locations filed on NHL trials. A trial with sites in several states counts in each.

New York 4 trials
California 4 trials
Maryland 3 trials
Texas 2 trials
Ohio 2 trials
Georgia 2 trials
Virginia 1 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this NHL page

9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NHL condition card totals 9 registered trials; most-linked intervention Rituximab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.